Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Start-ups
Affini-T raises $175 million to target KRAS cancers
by Rick Mullin
March 27, 2022
| A version of this story appeared in
Volume 100, Issue 11
Affini-T Therapeutics, a cell therapy company developing T cells targeting oncogenic driver mutations, has completed a $175 million financing co-led by Bayer’s investment unit. The company is a spin-off from the Fred Hutchinson Cancer Research Center, which is also an investor. Affini-T’s facilities in Boston and Seattle are developing therapies for patients with mutant variants of KRAS, considered the most prevalent oncogenic driver mutation in solid tumors.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter